Physicians and healthcare providers specializing in lung cancer will come together for a multidisciplinary event focused on breaking down barriers that prevent nearly half of Minnesota’s eligible patients from receiving essential biomarker testing—testing that is key to determining the best possible treatment.

7:30 – 8 a.m. Check-in, Breakfast, Exhibitor Showcase 

8 a.m. Session 1: Understanding Lung Cancer Biomarker Testing – Evolving U.S. Guidelines. Emilian Racila, MD, Anatomic and Clinical Pathologist, Associate Professor, University of Minnesota Medical School. Diana Oramas-Mogrovejo, MD, Assistant Professor, University of Minnesota Medical School.

9:30 a.m. Session 2: Practical Strategies to Overcome Barriers to Biomarker Testing for NSCLC Patients – Panel of physicians from healthcare systems serving Minnesotans living with lung cancer.

• • Moderated by Aaron S. Mansfield, MD, Mayo Clinic
  • Naomi Fujioka, MD, Medical Oncologist, Associate Professor, University of Minnesota Medical School
  • Bob Kratzke, MD, Medical Oncologist, Professor, Department Chair, University of Minnesota Medical School
  • Joe Leach, MD, Medical Oncologist, Associate Medical Director, Quality and Safety, Allina Health Cancer Institute
  • Ying-Chun Lo, MD, PhD, Pathologist, Mayo Clinic
  • Manish Patel, DO, Medical Oncologist, Associate Professor, University of Minnesota Medical School
  • Jaime Schneider, MD, PhD, Medical Oncologist, Dana-Farber Cancer Institute, Harvard Medical School
  • Aditi Singh, MD, MPH, Thoracic, Head & Neck Medical Oncologist, Minneapolis VA Healthcare System Assistant Professor of Medicine, University of Minnesota
  • Dan Mundt, MD, Medical Oncology & Hematology, Minnesota Oncology
  • Other speakers TBD

11 a.m. Session 3: The Value of Broad Panels that Capture Actionable and Non-Actionable Mutations (with tabletop discussions to follow)

• Working Through Reports on Actionable Lung Cancer Biomarkers/Available Targeted Therapies; Understanding Non-actionable Mutations that may influence clinical decision making (i.e. TP53 in EGFR patients or STK11/KEAP1). Deepti Behl, MD, Mayo Clinic, formerly Chief of Oncology/Medical Director, Sutter Sacramento Lung Cancer Program
• Balancing rapid/targeted NGS panel testing and broad panels for quick results. Sarah Kerr, MD, Pathologist, Co-Vice President of Hospital Pathology Associates and Chair of the Department of Pathology at Abbott Northwestern Hospital, Allina Health

Networking Lunch: 12:30-1:30 p.m.

 

 

THANK YOU EXHIBITORS!

PARTNER

 

ASSOCIATE

 

 

 

CONTRIBUTOR

 

 

 

 

PATRON

BREAKFAST SPONSOR

Foundation Medicine

 

 

For sponsor or exhibitor information contact Emma Carper-Jacobo at 952-454-0648 or

We look forward to connecting!